StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Gyre Therapeutics's price to sales ratio was 4.2× on Nov 11, 2026, against 6.3× a year earlier. Over the last 5 years it ranged from 4.2× to 434.9×, with a median of 10.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.2×−1.5
2025Dec 31, 20255.7×−4.2
2024Dec 31, 20249.9×−114.1
2022Jul 29, 2022124.0×+80.4
2021Dec 31, 202143.5×−57.1
2015Oct 30, 2015100.7×−320.2
2014Dec 31, 2014420.9×+382.3
2013Dec 31, 201338.6×+36.4
2012Dec 31, 20122.2×+0.1
2011Dec 30, 20112.1×−28.9
2010Dec 31, 201030.9×–

More Gyre Therapeutics figures

See a number that looks wrong?